$ISPC

iSpecimen Inc.

iSpecimen operates an online marketplace that connects life science researchers with healthcare providers and other suppliers of human biospecimens and associated data. Its customers primarily include biopharmaceutical companies, in vitro diagnostic companies, and government and academic institutions. The platform lets researchers search for and request specimens, place orders, and manage procurement, while suppliers list specimens and handle requests through the system. iSpecimen also manages marketing, sales, contracting, and compliance across the marketplace. The marketplace offers human biofluids, solid tissue, and hematopoietic stem and immune cells from healthy and diseased-state subjects, including remnant clinical specimens and samples collected specifically for research. iSpecimen makes money by procuring specimens from its provider network and distributing them to research clients, which pay iSpecimen; it shares a portion of the proceeds with suppliers. The company is headquartered in Woburn, Massachusetts.

0
1
0

No SEC Form 4 filings for $ISPC in the last 30 days.

See all $ISPC insider activity →
Med

iSpecimen 3Q 2026: Revenue $244.03K, EPS ($1.03) — 10-Q Summary

iSpecimen reported 3Q 2026 revenue of $244.03K, up 129% YoY, with specimen count rising 169% to 752. Net loss narrowed 20% due to lower operating expenses. Sales and marketing costs increased 21%, while technology and administrative expenses fell. Quote-to-purchase conversion ratio improved to 44%.

iSpecimen Raises $400,000 in Series D Preferred Stock Offering

iSpecimen raised $400,000 through a private placement of 500 Series D convertible preferred shares, with proceeds for working capital. The shares have an $8% annual dividend and conversion terms. The offering includes resale registration rights, E.F. Hutton's placement services, and a 90-day lock-up for insiders. According to the company, the financing is intended for general corporate purposes.

iSpecimen Inc. (ISPC): Entry into a Material Definitive Agreement

iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On November 6, 2026, iSpecimen Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”) for the issuance and sale, in a priva

ISPC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning ISPC (iSpecimen Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent ISPC coverage spans corporate actions, mergers & acquisitions and earnings.

What's driving ISPC

  • The quarter shows improving top-line and operating cost control, but still a net loss, keeping the stock sensitive to execution on conversion and margins.

    tradingview.com · Nov 17, 2026

  • The small capital raise may cause modest dilution and short-term price pressure.

    tradingview.com · Nov 9, 2026

  • The small private placement adds capital but introduces dilution and convertible preferred shares that may pressure the common stock.

    SEC EDGAR 8-K · Nov 9, 2026

  • The deal adds AI capabilities but dilutes existing shareholders with a 2.9 million‑share issuance subject to a five‑year lock‑up.

    SEC EDGAR 8-K · Nov 5, 2026

  • The deal adds AI capabilities and potential new revenue streams but introduces dilution.

    stocktitan.net · Nov 5, 2026

AlphAI scores every news story that mentions ISPC with an AI model for sentiment and relevance, and aggregates insider trades from iSpecimen Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ISPC

Score

iSpecimen Raises $400,000 in Series D Preferred Stock Offering

iSpecimen raised $400,000 through a private placement of 500 Series D convertible preferred shares, with proceeds for working capital. The shares have an $8% annual dividend and conversion terms. The offering includes resale registration rights, E.F. Hutton's placement services, and a 90-day lock-up for insiders. According to the company, the financing is intended for general corporate purposes.

$ISPCLowOffering· $400K · closed

iSpecimen Inc. (ISPC): Entry into a Material Definitive Agreement

iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On November 6, 2026, iSpecimen Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”) for the issuance and sale, in a priva

$ISPCMedM&A· acquirer · $4.5M · completed

iSpecimen Inc. (ISPC): Completion of Acquisition or Disposition of Assets

iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products New Agentic AI tools for protein discovery and disease trend prediction take iSpecimen beyond its biospecimen marketplace WOBURN, MA, Nov. 05, 2026 (

$ISPCMedShareholder vote

iSpecimen Inc. (ISPC): Submission of Matters to a Vote of Security Holders

iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. As previously reported, on October 9, 2026, iSpecimen Inc. (the “Company”) convened a special meeting of stockholders (the “Special Meeting”), at which the Company’s stockholders voted on Proposal Nos. 1, 3, 4 and 5,

$ISPCLowShareholder vote

iSpecimen Inc. (ISPC): Submission of Matters to a Vote of Security Holders

iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 9, 2026, iSpecimen Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). As of the close of business on August 12, 2026, the record date for the Special Meeting, there were 2,

$ISPCMedM&A· acquirer · $4.5M · definitive

iSpecimen Inc. (ISPC): Entry into a Material Definitive Agreement

iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 4, 2026, iSpecimen Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Agreement”) with Foldlab AI Ltd., a company organized under the laws of British Columbia (“Foldlab”

Related tickers